Research progress on the role of SIRT1 in heart failure.

Author: Yang-Ming ZHANG ¹ ; Mai LYU ¹ ; Chen-Yang WU ¹ ; Yuan-Xi CHEN ¹ ; Guo-Lan MA ¹ ; An-Tao LUO ¹
Author Information

1. Institute of Cardiovascular Diseases, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China.
Publication Type:English Abstract
MeSH: Heart Failure/metabolism*; Sirtuin 1/genetics*; Humans; Animals
From: Acta Physiologica Sinica 2025;77(2):361-373
CountryChina
Language:Chinese
Abstract: Heart failure (HF) is a common end-stage clinical manifestation of cardiovascular diseases, imposing substantial health-related burdens worldwide. With its high mortality rates and poor long-term prognosis, there is a pressing need for novel therapies. SIRT1, a nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase, has anti-cardiovascular aging properties and other cardioprotective effects, attracting much research attention in recent years. In addition, SIRT1 plays an important role in HF pathophysiology. This review summarized the roles of SIRT1 and its activators in HF, the changes of SIRT1 gene expression in cardiac tissues from animal models and HF patients, and the current status of clinical trials investigating SIRT1 activators as potential therapies for HF. This will provide new ideas for further exploration of pathological mechanisms and the development of clinical prevention strategies for HF.